Mode
Text Size
Log in / Sign up
Phase 2 N=19 Randomized Quadruple-blind Other

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

Cocaine Dependence

Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcome: Primary: Change in Visual Analog Questionnaire (VAQ) Score — 0.38; 3.75; 0.38; 40.63 units on a scale — p=<0.01

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Zonisamide (Drug); Placebo (Drug); Cocaine Hydrochloride (Drug); Neurocognitive and Performance Battery (Behavioral); Smoking Assessments (Behavioral)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Mar 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Visual Analog Questionnaire (VAQ) Score
0.38; 3.75; 0.38; 40.63; 32.63; 30.00 <0.01 sig
PRIMARY
Behavioral Choice Measures
0; 0; 0.25; 2; 2.38; 2.25 <0.01 sig
PRIMARY
Cocaine Craving
27.88; 27.25; 25; 19.13; 17.88; 13.5 0.16
SECONDARY
Drug Value Questionnaire
0; 0; 0; 9.29; 8.50; 7.63 <0.01 sig

Summary

This is a residential pilot trial to evaluate the pharmacodynamic interaction between zonisamide and cocaine, with the goal of evaluating zonisamide's potential for the treatment of cocaine dependence.

Eligibility Criteria

Inclusion Criteria

  • Age at least 21 years old, not older than 45 years.
  • Evidence of cocaine dependence.
  • Not seeking treatment for cocaine abuse.
  • Able and willing to be restricted to our unit for 6-7 weeks.
  • Able to answer frequent questionnaires reliably and consistently.
  • Smoker.

Exclusion Criteria

  • Allergy to Sulfonamide drugs (e.g. topiramate, zonisamide, sulfamethoxazole/trimethoprim).
  • Diabetes, respiratory insufficiency, renal tubular acidosis or renal insufficiency, heart failure, liver insufficiency, chronic diarrhea, other chronic diseases predisposing to acidosis.
  • Renal insufficiency defined as serum creatine > 1.30 mg/DL for males or > 1.03 mg/DL for females.
  • History of nephrolithiasis, unexplained hematuria on screening urinalysis.
  • History of head injury (with loss of consciousness longer than a few minutes).
  • History of seizure, or use of antiepileptic medications.
  • HIV positive individuals who meet AIDS by Centers for Disease Control (CDC) criteria or are on antiretroviral medications.
  • BMI 34.
  • Total cholesterol > 240mg%.
  • Serous psychiatric illness with psychosis, dementia.
  • Glaucoma, family history of glaucoma, one-sided blindness.
  • For female participants: being pregnant, lactating or not using an effective method of contraception.
  • Physical dependence on any drug other than cocaine, nicotine, or caffeine.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01137890). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search